[HTML][HTML] Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors
TA Yap, B O'Carrigan, MS Penney, JS Lim… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
TA Yap, B O'Carrigan, MS Penney, JS Lim, JS Brown, MJ de Miguel Luken, N Tunariu…
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.govPhase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination
With Carboplatin in Patients With Advanced Solid Tumors - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC7499606 Other Formats PDF (1.2M) Actions Cite Collections
Share Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
With Carboplatin in Patients With Advanced Solid Tumors - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC7499606 Other Formats PDF (1.2M) Actions Cite Collections
Share Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
Abstract
PURPOSE
Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin.
ncbi.nlm.nih.gov
